Lexicon Pharma tried and failed to get FDA approval for its SGLT inhibitor sotagliflozin for diabetes, but it has finally got the drug over the finish line – for a differe
AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio